Payment overview · 2025
General Payments
$773.60
57 reported records · 13 companies
Healthcare provider profile · identity verified
Robert Lavon Weeks, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNAH, GA · NPI 1487653168
Verified facts
What the public records show
CMS Open Payments records show Robert Lavon Weeks, M.D. received $773.60 in general payments during 2025 across 57 reported records.
Novo Nordisk Inc accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.99 | 23.8% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.93 | 19.4% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $106.20 | 13.7% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $99.01 | 12.8% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.04 | 6.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.54 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.72 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.60 | 4.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.12 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.61 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.70 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.45 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $773.60 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $140.93 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $140.93 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.09 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.55 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $106.20 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $99.01 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 272 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
272 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 915 | 263 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 872 | 271 |
| Levothyroxine Sodium | Levothyroxine Sodium | 706 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 691 | 197 |
| Ezetimibe | Ezetimibe | 361 | 108 |
| Furosemide | Furosemide | 308 | 79 |
| Farxiga | Dapagliflozin Propanediol | 306 | 80 |
| Metformin Hcl | Metformin Hcl | 292 | 80 |
| Tizanidine Hcl | Tizanidine Hcl | 284 | 93 |
| Ozempic | Semaglutide | 272 | 51 |
| Omeprazole | Omeprazole | 263 | 78 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 253 | 77 |
| Lisinopril | Lisinopril | 249 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 75 |
| Carvedilol | Carvedilol | 234 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 67 |
| Gabapentin | Gabapentin | 225 | 54 |
| Losartan Potassium | Losartan Potassium | 207 | 64 |
| Diclofenac Sodium | Diclofenac Sodium | 197 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 50 |
| Mirtazapine | Mirtazapine | 172 | 52 |
| Tramadol Hcl | Tramadol Hcl | 167 | 46 |
| Alprazolam | Alprazolam | 164 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 42 |
| Trazodone Hcl | Trazodone Hcl | 145 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 39 |
| Potassium Chloride | Potassium Chloride | 143 | 42 |
| Ibandronate Sodium | Ibandronate Sodium | 138 | 44 |
| Lorazepam | Lorazepam | 138 | 36 |
| Mounjaro | Tirzepatide | 134 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 131 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 40 |
| Allopurinol | Allopurinol | 127 | 38 |
| Famotidine | Famotidine | 127 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 39 |
| Glimepiride | Glimepiride | 126 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 122 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 120 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 23 |
| Eliquis | Apixaban | 119 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 112 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 32 |
| Metformin Hcl Er | Metformin Hcl | 102 | 30 |
| Simvastatin | Simvastatin | 100 | 30 |
| Prednisone | Prednisone | 99 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 25 |
| Trulicity | Dulaglutide | 95 | 17 |
| Bupropion Xl | Bupropion Hcl | 94 | 31 |
| Valsartan | Valsartan | 94 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 43 |
| Donepezil Hcl | Donepezil Hcl | 91 | 28 |
| Repaglinide | Repaglinide | 85 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 33 |
| Montelukast Sodium | Montelukast Sodium | 81 | 21 |
| Methylprednisolone | Methylprednisolone | 80 | 68 |
| Celecoxib | Celecoxib | 78 | 26 |
| Ibuprofen | Ibuprofen | 78 | 21 |
| Meloxicam | Meloxicam | 76 | 26 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Pregabalin | Pregabalin | 74 | 19 |
| Synthroid | Levothyroxine Sodium | 74 | 15 |
| Clonidine Hcl | Clonidine Hcl | 72 | 16 |
| Meclizine Hcl | Meclizine Hcl | 69 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 16 |
| Lovastatin | Lovastatin | 60 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 59 | 29 |
| Spironolactone | Spironolactone | 57 | 22 |
| Clonazepam | Clonazepam | 55 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Xarelto | Rivaroxaban | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 12 |
| Azelastine Hcl | Azelastine Hcl | 48 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 13 |
| Nifedipine Er | Nifedipine | 41 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | 11 |
| Atenolol | Atenolol | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 12 |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Finasteride | Finasteride | 36 | 15 |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Fluconazole | Fluconazole | 34 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Linzess | Linaclotide | 29 | 13 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 21 |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | 11 |
| Jardiance | Empagliflozin | 27 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 11 |
| Diazepam | Diazepam | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Estradiol | Estradiol | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 14 |
| Dexamethasone | Dexamethasone | 15 | 14 |
| Cefuroxime | Cefuroxime Axetil | 14 | 14 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Qtern | Dapagliflozin/Saxagliptin Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $773.60 · 57 records | Novo Nordisk Inc | ABRYSVO, CAMZYOS, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, Rybelsus, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error